

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Health Group Limited
中國衛生集團有限公司

(Carrying on business in Hong Kong as CHG HS Limited)

(Incorporated in Bermuda with limited liability)

(Stock Code: 673)

INSIDE INFORMATION
UPDATE ON THE CIVIL APPEAL FILED BY THE COMPANY
AND THE LITIGATION

This announcement is made by the board of directors (the “**Board**”) of China Health Group Limited (the “**Company**”) pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcement dated 13 September 2024 regarding the Writ filed by the Company and the announcement dated 26 May 2026 in relation to the update on the litigation (the “**Announcements**”). Unless otherwise defined, terms used herein shall have the same meanings as those defined in the Announcements.

As stated in the Announcements, the Civil Judgment dated 12 May 2026 issued by the Chengde Intermediate Court was served on 21 May 2026. Pursuant to the Civil Judgment, if any party disagrees with the judgment made in the Civil Judgment, it may file an appeal with the Chengde Intermediate Court within the prescribed period from the date of service of the Civil Judgment to appeal to the Higher People’s Court of Hebei Province (the “**Hebei Higher Court**”).

The Company would like to provide an update to its shareholders and potential investors. The Company has filed a civil appeal dated 3 June 2026 (the “**Civil Appeal**”) with the Chengde Intermediate Court in respect of the Civil Judgment, and has paid the case acceptance fee on 6 July 2026 in accordance with the law.

Pursuant to the Civil Appeal, the claims of the Company's appeal are as follows:

1. revocation of the Civil Judgment;
2. reversion of the judgment to support all of the Company's claims made in the first-instance litigation;
3. the Defendants to jointly bear the litigation costs for both the first-instance and second-instance litigations.

The Civil Appeal of the Company is mainly based on, among others, the following grounds that: the Chengde Intermediate Court erred in its determination of certain key facts of the case, omitted crucial evidence, and misapplied the law during the trial. Accordingly, the Company has filed an appeal with the Hebei Higher Court in accordance with the law to safeguard the legitimate rights and interests of the Company and its shareholders.

The Company will publish further announcement(s) to inform the shareholders and potential investors of any material developments in relation to the above matters as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
China Health Group Limited
Cao Xu
Chairman of the Board and Executive Director

Hong Kong, 13 July 2026

As of the date of this announcement, the Board comprises three executive Directors, namely, Mr. Cao Xu (Chairman), Mr. Chung Ho and Ms. Ying Rensi; two non-executive Directors, namely, Mr. Ying Wei and Mr. Huang Lianhai; and three independent non-executive Directors, namely, Mr. Li Hongyi, Mr. Wu Hui and Ms. Yang Huimin.